{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:50:55Z","timestamp":1781783455835,"version":"3.54.5"},"reference-count":25,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) represents a major global health concern due to biological heterogeneity and the complexity of its underlying molecular pathways, which contribute to substantial morbidity and mortality. Ongoing research continues to elucidate distinct molecular mechanisms that may inform diagnostic and therapeutic strategies. Among these, the prostate-specific membrane antigen (PSMA) has emerged as a pivotal biomarker and therapeutic target in PCa. PSMA is indirectly modulated by androgen signalling through the androgen receptor (AR) pathway and has been observed to undergo transient upregulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa. This transient increase in PSMA expression\u2014termed the \u2018PSMA flare phenomenon\u2019\u2014may enhance the sensitivity and accuracy of PSMA-based molecular imaging and disease staging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The DARO-flare trials are a prospective, single-centre, interventional, phase I\u2013II proof-of-concept study evaluating whether short-term administration of darolutamide induces a PSMA-flare in patients with hormone-sensitive PCa. The cohort being investigated comprises patients with oligometastatic recurrence following prior therapy with curative intent.<\/jats:p>\n                    <jats:p>Within the cohort, participants are randomised (1:1) to receive darolutamide 600 mg two times a day for either 7 or 14 days. All participants undergo baseline PSMA positron emission tomography (PET)\/CT imaging as standard-of-care and two follow-up scans on days 7 and 14.<\/jats:p>\n                    <jats:p>The primary endpoint was the change in the number of PSMA-expressing PCa lesions and\/or PSMA expression per lesion maximum standardised uptake value on repeated PSMA PET\/CT, indicative of a darolutamide flare response. Secondary endpoints included the impact on clinical management decisions, defined as a treatment change following short-course darolutamide, tolerability and toxicity as assessed by adverse event reporting, and patient-reported outcomes related to quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been approved by the Medical Ethics Committee (METC) Amsterdam UMC and adheres to the Declaration of Helsinki. Written informed consent is obtained from all participants. Study findings will be disseminated through peer-reviewed publications and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      2025-520482-52-03 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2025-520482-52-03?lang=en\">https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2025-520482-52-03?lang=en<\/jats:ext-link>\n                      , protocol nr 6.0).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115888","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:50:46Z","timestamp":1781779846000},"page":"e115888","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer \u2013 study protocol"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-7409","authenticated-orcid":false,"given":"Suzanne","family":"van der Gaag","sequence":"first","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Vis","sequence":"additional","affiliation":[{"name":"Department of Urology, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Bartelink","sequence":"additional","affiliation":[{"name":"Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hendrikse","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E","family":"Oprea-Lager","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026061803502022000_16.6.e115888.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer","volume":"22","author":"Staniszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026061803502022000_16.6.e115888.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res"},{"key":"2026061803502022000_16.6.e115888.3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"Murga","year":"2015","journal-title":"Prostate"},{"key":"2026061803502022000_16.6.e115888.4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Kranzb\u00fchler","year":"2018","journal-title":"Prostate"},{"key":"2026061803502022000_16.6.e115888.5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/pros.23868","article-title":"Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177Lu-PSMA-617 in LNCaP cells","volume":"79","author":"Kranzb\u00fchler","year":"2019","journal-title":"Prostate"},{"key":"2026061803502022000_16.6.e115888.6","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00432-021-03583-w","article-title":"Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga-PSMA uptake in LNCaP cells","volume":"147","author":"Mathy","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026061803502022000_16.6.e115888.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106383108"},{"key":"2026061803502022000_16.6.e115888.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0342"},{"key":"2026061803502022000_16.6.e115888.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.181800"},{"key":"2026061803502022000_16.6.e115888.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"L\u00fcckerath","year":"2018","journal-title":"EJNMMI Res"},{"key":"2026061803502022000_16.6.e115888.11","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/RLU.0000000000002273","article-title":"Bone Flare to Androgen Deprivation Therapy in Metastatic, Hormone-Sensitive Prostate Cancer on 68Ga-Prostate-Specific Membrane Antigen PET\/CT","volume":"43","author":"Zacho","year":"2018","journal-title":"Clin Nucl Med"},{"key":"2026061803502022000_16.6.e115888.12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"2026061803502022000_16.6.e115888.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2026061803502022000_16.6.e115888.14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bju.15491","article-title":"ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)","volume":"128","author":"Emmett","year":"2021","journal-title":"BJU Int"},{"key":"2026061803502022000_16.6.e115888.15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","article-title":"New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide","volume":"47","author":"Rosar","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061803502022000_16.6.e115888.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026061803502022000_16.6.e115888.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268340"},{"key":"2026061803502022000_16.6.e115888.18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026061803502022000_16.6.e115888.19","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061803502022000_16.6.e115888.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2026061803502022000_16.6.e115888.21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur Urol"},{"key":"2026061803502022000_16.6.e115888.22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-023-01268-w","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide","volume":"62","author":"Podgor\u0161ek","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2026061803502022000_16.6.e115888.23","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"2026061803502022000_16.6.e115888.24","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13211"},{"key":"2026061803502022000_16.6.e115888.25","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.4081\/aiua.2024.12132","article-title":"Ductal prostate cancer staging: Role of PSMA PET\/CT","volume":"96","author":"Pepe","year":"2024","journal-title":"Arch Ital Urol Androl"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:50:49Z","timestamp":1781779849000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjopen-2025-115888"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115888","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}